INS and polyneuropathy: It is possible that the relatively late start of insulin treatment and metabolic control explains the higher risk of diabetic retinopathy and polyneuropathy [13], initially manifested by reduced capillary density in the SCP or RPE dysfunction, and, as we show, reduced choriocapillary flow.